Health Affairs, 27, no. 4 (2008): w315-w317 (Published online 17 June 2008) doi: 10.1377/hlthaff.27.4.w315 © 2008 by Project HOPE	New Online   House Health Reform Bill   Paying for Reform   Vetting AHIP's Report   HIV/AIDS Costs   Brief: Insurance Reform   HA Blog Top 10

This Article Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when Comments are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Culliton, B. J. Search for Related Content PubMed PubMed Citation Articles by Culliton, B. J. Related Collections Legal/Regulatory Issues Pharmaceuticals Research And Technology Related Article

Web Exclusives

INTERVIEW

Is Special FDA Regulation Of Nanomedicine Needed? A Conversation With Norris E. Alderson

Cutting-edge research in nanomedicine dominates studies in drug delivery, medical imaging, and the development of new devices. Materials and devices the size of molecules, and even individual atoms, make it possible to see a tumor when it is no more than a few atoms in size. By using material in this size range, drugs can go directly to tumors or inflamed arteries, bypassing healthy tissue. In this interview Norris Alderson of the Food and Drug Administration discusses the present and future state of nanomedicine as it applies to health care, taking into consideration benefits, risks, and how much is still unknown.

                      What's this?

Related Article

• Barbara J. Culliton
  Nanomedicine—The Power Of Proteins: A Conversation With Lance Liotta And Emanual Petricoin
  Health Affairs, July/August 2008; 27(4): w310-w314.
  [Abstract] [Full Text] [PDF]